Dippmann, Carolin
Schmitz, Martina
Wunsch, Kristina
Schütze, Stefanie
Beer, Katrin
Greinke, Christiane
Ikenberg, Hans
Hoyer, Heike
Runnebaum, Ingo B.
Hansel, Alfred
Dürst, Matthias http://orcid.org/0000-0003-1235-1150
Article History
Received: 4 September 2020
Accepted: 28 October 2020
First Online: 11 November 2020
Ethics approval and consent to participate
: This work was approved by the ethics committee of the Friedrich Schiller University Jena (Reference Numbers 2174-12/07 and 3471-06/12). Samples from CytoMol comprise anonymized surplus samples from routine cervical cancer screening that otherwise would have been discarded. The Department of Gynaecology and Reproductive Medicine at the Jena University Hospital contributed to the study with pseudonymized surplus samples. The study was performed following the guideline of the Declaration of Helsinki.
: Not applicable.
: MS, AH, KW, and MD are minority shareholders and/or employees of oncgnostics GmbH, a company that aims to commercialize DNA methylation markers. CD receives a PhD fellowship financed by oncgnostics GmbH and ESF.